HK Stock MarketDetailed Quotes

FOSUN PHARMA (02196)

Watchlist
  • 19.110
  • -0.470-2.40%
Market Closed Apr 30 16:07 CST
50.82BMarket Cap12.90P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

FOSUN PHARMA (02196) Income Statement

All
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2026
(FY)Dec 31, 2025
(Q9)Sep 30, 2025
(Q6)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q9)Sep 30, 2024
(Q6)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
Turnover
6.93%10.07B
1.44%41.5B
-4.91%29.39B
-4.70%19.43B
-7.26%9.42B
-0.82%40.91B
0.69%30.91B
-4.38%20.38B
-6.56%10.16B
-5.85%41.25B
Operating income
6.93%10.07B
1.44%41.5B
-4.91%29.39B
-4.70%19.43B
-7.26%9.42B
-0.82%40.91B
0.69%30.91B
-4.38%20.38B
-6.56%10.16B
-5.85%41.25B
Cost of sales
----
2.65%-20.8B
----
3.25%-10.12B
----
1.06%-21.37B
----
2.20%-10.46B
----
6.80%-21.6B
Operating expenses
-2.98%-5.07B
2.65%-20.8B
4.18%-15.23B
3.25%-10.12B
3.10%-4.92B
1.06%-21.37B
-0.70%-15.89B
2.20%-10.46B
4.10%-5.08B
6.80%-21.6B
Gross profit
11.25%5.01B
5.90%20.7B
-5.69%14.17B
-6.23%9.3B
-11.41%4.5B
-0.55%19.54B
0.68%15.02B
-6.57%9.92B
-8.90%5.08B
-4.79%19.65B
Selling expenses
-6.06%-2.25B
-5.91%-9.19B
4.90%-6.27B
1.29%-4.21B
5.11%-2.13B
10.63%-8.68B
8.78%-6.59B
15.87%-4.27B
10.93%-2.24B
-5.90%-9.71B
Administrative expenses
-4.53%-1.02B
-7.32%-4.76B
2.46%-3.07B
1.17%-2.12B
2.91%-973.13M
1.23%-4.44B
0.77%-3.14B
-2.17%-2.15B
-1.13%-1B
-14.80%-4.5B
Research and development expenses
-21.61%-896.79M
-10.10%-4.01B
-3.08%-2.73B
7.79%-1.72B
11.10%-737.45M
16.15%-3.64B
16.07%-2.65B
12.77%-1.86B
14.38%-829.57M
-1.02%-4.35B
Profit from asset sales
490.77%1.37M
----
2,397.01%62.76M
----
-180.86%-351K
----
-60.10%2.51M
----
185.51%434.1K
----
Revaluation surplus
157.11%160.92M
----
-253.06%-375.11M
----
-1,299.12%-281.74M
----
-113.18%-106.25M
----
86.36%-20.14M
----
-Changes in the fair value of other assets
157.11%160.92M
----
-253.06%-375.11M
----
-1,299.12%-281.74M
----
-113.18%-106.25M
----
86.36%-20.14M
----
Impairment and provision
95.49%-942.22K
-13.15%-125.18M
-37.77%-131.45M
24.46%-28.73M
-98.37%-20.89M
16.14%-110.63M
74.38%-95.41M
34.39%-38.04M
58.87%-10.53M
-101.82%-131.93M
-Other impairment is provision
95.49%-942.22K
-13.15%-125.18M
-37.77%-131.45M
24.46%-28.73M
-98.37%-20.89M
16.14%-110.63M
74.38%-95.41M
34.39%-38.04M
58.87%-10.53M
-101.82%-131.93M
Special items of operating profit
-50.93%673.1M
69.51%1.55B
91.89%3.37B
18,337.96%1.06B
229.14%1.37B
-15.74%914.58M
-29.30%1.76B
-99.42%5.73M
-49.69%416.77M
353.64%1.09B
Operating profit
-2.34%1.6B
15.87%4.15B
20.89%4.79B
41.46%2.28B
25.69%1.64B
74.56%3.58B
-3.32%3.96B
-1.76%1.61B
-22.91%1.3B
-40.08%2.05B
Financing income
-5.60%72.14M
-19.48%300.5M
-15.34%236.79M
-13.50%163.45M
-23.33%76.42M
2.63%373.21M
5.31%279.71M
--188.97M
10.60%99.67M
28.66%363.65M
Financing cost
10.02%-296.51M
11.63%-1.27B
8.79%-974.03M
8.00%-652.78M
5.33%-329.53M
-8.08%-1.43B
-12.68%-1.07B
---709.55M
-22.14%-348.09M
-37.46%-1.32B
Share of profits of associates
----
5.70%1.93B
----
-1.38%934.14M
----
-23.40%1.83B
----
-15.29%947.2M
----
15.36%2.39B
Share of profit from joint venture company
----
95.39%-8.5M
----
95.77%-4.48M
----
8.72%-184.41M
----
-10.47%-105.88M
----
13.63%-202.03M
Special items of earning before tax
-58.80%-17.83M
----
-92.72%-69.42M
----
-281.92%-11.23M
----
27.58%-36.02M
----
93.06%-2.94M
----
Earning before tax
0.74%1.36B
22.61%5.11B
24.93%3.84B
40.77%2.72B
32.32%1.35B
27.23%4.17B
-6.71%3.07B
-27.44%1.93B
-26.46%1.02B
-28.46%3.28B
Tax
----
-31.55%-864.05M
----
-62.08%-618.27M
----
-77.76%-656.84M
----
37.49%-381.47M
----
41.06%-369.5M
After-tax profit from continuing operations
14.66%1.08B
20.94%4.25B
21.34%3.06B
35.52%2.1B
19.76%941.57M
20.81%3.51B
-5.10%2.52B
-24.45%1.55B
-29.44%786.22M
-26.46%2.91B
Earning after tax
14.66%1.08B
20.94%4.25B
21.34%3.06B
35.52%2.1B
19.76%941.57M
20.81%3.51B
-5.10%2.52B
-24.45%1.55B
-29.44%786.22M
-26.46%2.91B
Minority profit
18.10%208.8M
18.16%877.37M
4.91%532.8M
22.56%398.24M
0.18%176.81M
45.94%742.55M
36.99%507.88M
21.36%324.93M
38.66%176.49M
134.84%508.8M
Profit attributable to shareholders
13.87%870.83M
21.69%3.37B
25.50%2.52B
38.96%1.7B
25.42%764.76M
15.48%2.77B
-11.93%2.01B
-31.33%1.22B
-38.22%609.73M
-35.81%2.4B
Basic earnings per share
13.79%0.33
22.12%1.27
26.67%0.95
39.13%0.64
26.09%0.29
15.56%1.04
-12.79%0.75
-31.34%0.46
-37.84%0.23
-37.06%0.9
Diluted earnings per share
13.79%0.33
22.12%1.27
26.67%0.95
39.13%0.64
26.09%0.29
15.56%1.04
-11.76%0.75
-31.34%0.46
-37.84%0.23
-37.06%0.9
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
Audit Opinions
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
Auditor
--
Ernst & Young Huaming Accounting Firm (Special General Partnership)
--
--
--
Ernst & Young Huaming Accounting Firm (Special General Partnership)
--
--
--
Ernst & Young Huaming Accounting Firm (Special General Partnership)
(Q1)Mar 31, 2026(FY)Dec 31, 2025(Q9)Sep 30, 2025(Q6)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q9)Sep 30, 2024(Q6)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023
Turnover 6.93%10.07B1.44%41.5B-4.91%29.39B-4.70%19.43B-7.26%9.42B-0.82%40.91B0.69%30.91B-4.38%20.38B-6.56%10.16B-5.85%41.25B
Operating income 6.93%10.07B1.44%41.5B-4.91%29.39B-4.70%19.43B-7.26%9.42B-0.82%40.91B0.69%30.91B-4.38%20.38B-6.56%10.16B-5.85%41.25B
Cost of sales ----2.65%-20.8B----3.25%-10.12B----1.06%-21.37B----2.20%-10.46B----6.80%-21.6B
Operating expenses -2.98%-5.07B2.65%-20.8B4.18%-15.23B3.25%-10.12B3.10%-4.92B1.06%-21.37B-0.70%-15.89B2.20%-10.46B4.10%-5.08B6.80%-21.6B
Gross profit 11.25%5.01B5.90%20.7B-5.69%14.17B-6.23%9.3B-11.41%4.5B-0.55%19.54B0.68%15.02B-6.57%9.92B-8.90%5.08B-4.79%19.65B
Selling expenses -6.06%-2.25B-5.91%-9.19B4.90%-6.27B1.29%-4.21B5.11%-2.13B10.63%-8.68B8.78%-6.59B15.87%-4.27B10.93%-2.24B-5.90%-9.71B
Administrative expenses -4.53%-1.02B-7.32%-4.76B2.46%-3.07B1.17%-2.12B2.91%-973.13M1.23%-4.44B0.77%-3.14B-2.17%-2.15B-1.13%-1B-14.80%-4.5B
Research and development expenses -21.61%-896.79M-10.10%-4.01B-3.08%-2.73B7.79%-1.72B11.10%-737.45M16.15%-3.64B16.07%-2.65B12.77%-1.86B14.38%-829.57M-1.02%-4.35B
Profit from asset sales 490.77%1.37M----2,397.01%62.76M-----180.86%-351K-----60.10%2.51M----185.51%434.1K----
Revaluation surplus 157.11%160.92M-----253.06%-375.11M-----1,299.12%-281.74M-----113.18%-106.25M----86.36%-20.14M----
-Changes in the fair value of other assets 157.11%160.92M-----253.06%-375.11M-----1,299.12%-281.74M-----113.18%-106.25M----86.36%-20.14M----
Impairment and provision 95.49%-942.22K-13.15%-125.18M-37.77%-131.45M24.46%-28.73M-98.37%-20.89M16.14%-110.63M74.38%-95.41M34.39%-38.04M58.87%-10.53M-101.82%-131.93M
-Other impairment is provision 95.49%-942.22K-13.15%-125.18M-37.77%-131.45M24.46%-28.73M-98.37%-20.89M16.14%-110.63M74.38%-95.41M34.39%-38.04M58.87%-10.53M-101.82%-131.93M
Special items of operating profit -50.93%673.1M69.51%1.55B91.89%3.37B18,337.96%1.06B229.14%1.37B-15.74%914.58M-29.30%1.76B-99.42%5.73M-49.69%416.77M353.64%1.09B
Operating profit -2.34%1.6B15.87%4.15B20.89%4.79B41.46%2.28B25.69%1.64B74.56%3.58B-3.32%3.96B-1.76%1.61B-22.91%1.3B-40.08%2.05B
Financing income -5.60%72.14M-19.48%300.5M-15.34%236.79M-13.50%163.45M-23.33%76.42M2.63%373.21M5.31%279.71M--188.97M10.60%99.67M28.66%363.65M
Financing cost 10.02%-296.51M11.63%-1.27B8.79%-974.03M8.00%-652.78M5.33%-329.53M-8.08%-1.43B-12.68%-1.07B---709.55M-22.14%-348.09M-37.46%-1.32B
Share of profits of associates ----5.70%1.93B-----1.38%934.14M-----23.40%1.83B-----15.29%947.2M----15.36%2.39B
Share of profit from joint venture company ----95.39%-8.5M----95.77%-4.48M----8.72%-184.41M-----10.47%-105.88M----13.63%-202.03M
Special items of earning before tax -58.80%-17.83M-----92.72%-69.42M-----281.92%-11.23M----27.58%-36.02M----93.06%-2.94M----
Earning before tax 0.74%1.36B22.61%5.11B24.93%3.84B40.77%2.72B32.32%1.35B27.23%4.17B-6.71%3.07B-27.44%1.93B-26.46%1.02B-28.46%3.28B
Tax -----31.55%-864.05M-----62.08%-618.27M-----77.76%-656.84M----37.49%-381.47M----41.06%-369.5M
After-tax profit from continuing operations 14.66%1.08B20.94%4.25B21.34%3.06B35.52%2.1B19.76%941.57M20.81%3.51B-5.10%2.52B-24.45%1.55B-29.44%786.22M-26.46%2.91B
Earning after tax 14.66%1.08B20.94%4.25B21.34%3.06B35.52%2.1B19.76%941.57M20.81%3.51B-5.10%2.52B-24.45%1.55B-29.44%786.22M-26.46%2.91B
Minority profit 18.10%208.8M18.16%877.37M4.91%532.8M22.56%398.24M0.18%176.81M45.94%742.55M36.99%507.88M21.36%324.93M38.66%176.49M134.84%508.8M
Profit attributable to shareholders 13.87%870.83M21.69%3.37B25.50%2.52B38.96%1.7B25.42%764.76M15.48%2.77B-11.93%2.01B-31.33%1.22B-38.22%609.73M-35.81%2.4B
Basic earnings per share 13.79%0.3322.12%1.2726.67%0.9539.13%0.6426.09%0.2915.56%1.04-12.79%0.75-31.34%0.46-37.84%0.23-37.06%0.9
Diluted earnings per share 13.79%0.3322.12%1.2726.67%0.9539.13%0.6426.09%0.2915.56%1.04-11.76%0.75-31.34%0.46-37.84%0.23-37.06%0.9
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKAS
Audit Opinions --Unqualified Opinion------Unqualified Opinion------Unqualified Opinion
Auditor --Ernst & Young Huaming Accounting Firm (Special General Partnership)------Ernst & Young Huaming Accounting Firm (Special General Partnership)------Ernst & Young Huaming Accounting Firm (Special General Partnership)

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +7.99%
Sample Name
Sample Code
 +4.00%
Sample Name
Sample Code
 +2.86%
4
SINOPEC CORP
00386
+2.22%
5
CNOOC
00883
+1.66%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +46.25%
Sample Name
Sample Code
 +33.47%
Sample Name
Sample Code
 +26.48%
4
Loongson Technology Corporation
688047
+24.63%
5
Rockchip Electronics
603893
+19.54%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -